UBS Group Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price

Charles River Laboratories International (NYSE:CRL) had its price target boosted by equities researchers at UBS Group from $170.00 to $175.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. UBS Group’s price objective would suggest a potential upside of 4.29% from the stock’s current price.

CRL has been the subject of several other research reports. JPMorgan Chase & Co. upped their target price on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Robert W. Baird set a $193.00 price objective on Charles River Laboratories International in a report on Thursday, February 19th. Mizuho decreased their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Friday, February 20th. Evercore upped their price target on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Finally, Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, December 15th. Ten investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $203.57.

Charles River Laboratories International Trading Up 1.1%

Shares of NYSE:CRL traded up $1.75 during midday trading on Wednesday, reaching $167.81. The company’s stock had a trading volume of 657,463 shares, compared to its average volume of 1,002,097. The firm has a market cap of $8.26 billion, a price-to-earnings ratio of -56.76, a price-to-earnings-growth ratio of 2.81 and a beta of 1.63. The business has a 50 day moving average price of $199.10 and a 200 day moving average price of $179.84. Charles River Laboratories International has a 1 year low of $91.86 and a 1 year high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The company had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm’s revenue was down .8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Research analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tema Etfs LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $26,000. Rothschild Investment LLC increased its position in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the period. Neo Ivy Capital Management bought a new stake in Charles River Laboratories International during the 2nd quarter valued at $29,000. Atlantic Union Bankshares Corp acquired a new position in Charles River Laboratories International during the 3rd quarter worth $31,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter worth $42,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.